GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » PURE Bioscience Inc (OTCPK:PURE) » Definitions » Return-on-Tangible-Equity

PURE Bioscience (PURE Bioscience) Return-on-Tangible-Equity : 0.00% (As of Jan. 2024)


View and export this data going back to 1996. Start your Free Trial

What is PURE Bioscience Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PURE Bioscience's annualized net income for the quarter that ended in Jan. 2024 was $-4.01 Mil. PURE Bioscience's average shareholder tangible equity for the quarter that ended in Jan. 2024 was $-0.85 Mil. Therefore, PURE Bioscience's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2024 was N/A%.

The historical rank and industry rank for PURE Bioscience's Return-on-Tangible-Equity or its related term are showing as below:

PURE' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1364.25   Med: -233.58   Max: 0.16
Current: -964.29

During the past 13 years, PURE Bioscience's highest Return-on-Tangible-Equity was 0.16%. The lowest was -1,364.25%. And the median was -233.58%.

PURE's Return-on-Tangible-Equity is ranked worse than
99.61% of 1791 companies
in the Consumer Packaged Goods industry
Industry Median: 7.7 vs PURE: -964.29

PURE Bioscience Return-on-Tangible-Equity Historical Data

The historical data trend for PURE Bioscience's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PURE Bioscience Return-on-Tangible-Equity Chart

PURE Bioscience Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,020.87 0.16 -63.21 -101.54 -189.48

PURE Bioscience Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -167.36 -210.96 -540.67 - -

Competitive Comparison of PURE Bioscience's Return-on-Tangible-Equity

For the Household & Personal Products subindustry, PURE Bioscience's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PURE Bioscience's Return-on-Tangible-Equity Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where PURE Bioscience's Return-on-Tangible-Equity falls into.



PURE Bioscience Return-on-Tangible-Equity Calculation

PURE Bioscience's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jul. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jul. 2023 )  (A: Jul. 2022 )(A: Jul. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jul. 2023 )  (A: Jul. 2022 )(A: Jul. 2023 )
=-3.961/( (3.909+0.272 )/ 2 )
=-3.961/2.0905
=-189.48 %

PURE Bioscience's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=-4.008/( (-0.383+-1.321)/ 2 )
=-4.008/-0.852
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


PURE Bioscience  (OTCPK:PURE) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


PURE Bioscience Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of PURE Bioscience's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


PURE Bioscience (PURE Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
771 Jamacha Road, No. 512, El Cajon, CA, USA, 92019
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use.
Executives
Robert F Bartlett director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Bernard Blotner director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Tom Y Lee director 1807 SAN GABRIEL BLVD., SAN GABRIEL CA 91776
David Rendall director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Kristin Taylor director 13500 EVENING CREEK DRIVE N, SUITE 550, SAN DIEGO CA 92128
Dale Okuno director 35 N. ARROYO PARKWAY, SUITE 1, PASADENA CA 91103
Ivan Chen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Thomas Richard Myers officer: Chief Operating Officer 1725 GILLESPIE WAY, EL CAJON CA 92130
Henry R. Lambert director, officer: Chief Executive Officer 1725 GILLESPIE WAY, EL CAJON CA 92020
Elisabeth Hagen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Janet Risi Field director 9200 SOUTH DADELAND BOULEVARD, SUITE 800, MIAMI FL 33156
Franchise Brands, Llc 10 percent owner 325 BIC DRIVE, MILFORD CT 06461
Mark Stuart Elliott officer: Vice President, Finance 1725 GILLESPIE WAY, EL CAJON CA 92020
William Otis director 1725 GILLESPIE WAY, EL CAJON CA 92020
David M Theno director 1725 GILLESPIE WAY, EL CAJON CA 92020